Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zastaprazan Citrate
Therapeutic Area : Gastroenterology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Onconic Receives MFDS Approval for JAQBO, a New GERD Treatment
Details : Jaqbo (zastaprazan citrate) is a next-generation potassium competitive blocker, small molecule drug candidate. It is being evaluated for the treatment of gastroesophageal reflux disease in adults.
Brand Name : Jaqbo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 25, 2024
Lead Product(s) : Zastaprazan Citrate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Zastaprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Livzon Pharmaceutical Group
Deal Size : $127.5 million
Deal Type : Acquisition
Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million
Details : Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan,...
Brand Name : JP 1366
Molecule Type : Small molecule
Upfront Cash : $15.0 million
March 14, 2023
Lead Product(s) : Zastaprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Livzon Pharmaceutical Group
Deal Size : $127.5 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
